Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating gemcitabine maintenance versus continued nab-paclitaxel + gemcitabine after induction in first-line metastatic pancreatic cancer
2014-004086-24Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Overall survival. Started Oct 2015; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2014-004086-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004086-24.